Inhibikase Therapeutics, Inc. · NASDAQ:IKT

Trails Edge Capital Partners, LP reported a 6.10% stake in Inhibikase Therapeutics, Inc. (Schedule 13G/A)

Event Mar 31, 2026 · Filed May 15, 2026

Trails Edge Capital Partners, LP reported a 6.10% stake in Inhibikase Therapeutics, Inc., 8,057,345 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G/A).

Stake
6.10%
Shares
8,057,345
Intent
Passive
What changed
Stake changed
Filed together
3 holders

The filing in full

HolderStakeShares
Trails Edge Capital Partners, LP6.10%8,057,345
Trails Edge Biotechnology Master Fund, LP6.10%8,057,345
Ortav Yehudai6.10%8,057,345

Source

View original at SEC

Related